Phase II study of Depocyt [cytarabine] therapy for CNS prophylaxis in high-risk patients after hematopoietic stem cell transplant

Trial Profile

Phase II study of Depocyt [cytarabine] therapy for CNS prophylaxis in high-risk patients after hematopoietic stem cell transplant

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2013

At a glance

  • Drugs Cytarabine (Primary) ; Cytarabine (Primary)
  • Indications CNS cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Mar 2013 Status changed from recruiting to discontinued as reported by the MD Anderson cancer Centre record.
    • 23 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top